Literature DB >> 18377702

Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine.

Styliani Vlachou1, Fygaleia Stamatopoulou, George G Nomikos, George Panagis.   

Abstract

Cannabinoids, in contrast to typical drugs of abuse, have been shown to exert complex effects on behavioural reinforcement and psychomotor function. We have shown that cannabinoid agonists lack reinforcing/rewarding properties in the intracranial self-stimulation (ICSS) paradigm and that the CB1 receptor (CB1R) agonist WIN55,212-2 attenuates the reward-facilitating actions of cocaine. We sought to determine the effects of the endocannabinoid neurotransmission enhancer AM-404 (1, 3, 10, 30 mg/kg) on the changes in ICSS threshold and locomotion elicited by cocaine and extend the study of the effects of WIN55,212-2 (0.3, 1, 3 mg/kg) on cocaine-induced hyperlocomotion. AM-404 did not exhibit reward-facilitating properties, and actually increased self-stimulation threshold at the highest dose. Cocaine significantly reduced self-stimulation threshold, without altering maximal rates of responding. AM-404 (10 mg/kg) attenuated this action of cocaine, an effect which was reversed by pretreatment with the selective CB1R antagonist SR141716A. WIN55,212-2 decreased locomotion at the two highest doses, an effect that was blocked by SR141716A; AM-404 had no effect on locomotion. Cocaine caused a significant, dose-dependent increase in locomotion, which was reduced by WIN55,212-2 and AM-404. SR141716A blocked the effects of WIN55,212-2 and AM-404 on cocaine-induced hyperlocomotion. SR141716A alone had no effect on ICSS threshold or locomotion. These results indicate that cannabinoids may interfere with brain reward systems responsible for the expression of acute reinforcing/rewarding properties of cocaine, and provide further evidence that the cannabinoid system could be explored as a potential drug discovery target for the treatment of psychostimulant addiction and pathological states associated with psychomotor overexcitability.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18377702     DOI: 10.1017/S1461145708008717

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  14 in total

1.  Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.

Authors:  Jason M Wiebelhaus; Travis W Grim; Robert A Owens; Matthew F Lazenka; Laura J Sim-Selley; Rehab A Abdullah; Micah J Niphakis; Robert E Vann; Benjamin F Cravatt; Jenny L Wiley; S Stevens Negus; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2014-11-14       Impact factor: 4.030

Review 2.  Endocannabinoid signalling in reward and addiction.

Authors:  Loren H Parsons; Yasmin L Hurd
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

Review 3.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

4.  The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice.

Authors:  Bogna M Ignatowska-Jankowska; Pretal P Muldoon; Aron H Lichtman; M Imad Damaj
Journal:  Psychopharmacology (Berl)       Date:  2013-05-08       Impact factor: 4.530

5.  Role of serotonin 5-HT2A and 5-HT2C receptors on brain stimulation reward and the reward-facilitating effect of cocaine.

Authors:  Vicky Katsidoni; Kalliopi Apazoglou; George Panagis
Journal:  Psychopharmacology (Berl)       Date:  2010-06-25       Impact factor: 4.530

6.  Cannabinoid conditioned reward and aversion: behavioral and neural processes.

Authors:  Jennifer E Murray; Rick A Bevins
Journal:  ACS Chem Neurosci       Date:  2010-03-10       Impact factor: 4.418

7.  AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking.

Authors:  Islam Gamaleddin; Mihail Guranda; Maria Scherma; Walter Fratta; Alexandros Makriyannis; Subramanian K Vadivel; Steven R Goldberg; Bernard Le Foll
Journal:  J Psychopharmacol       Date:  2013-02-20       Impact factor: 4.153

Review 8.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

9.  Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.

Authors:  Charles W Schindler; Godfrey H Redhi; Kiran Vemuri; Alexandros Makriyannis; Bernard Le Foll; Jack Bergman; Steven R Goldberg; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2016-02-18       Impact factor: 7.853

10.  Cannabinoid Modulation of Food-Cocaine Choice in Male Rhesus Monkeys.

Authors:  William S John; Thomas J Martin; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2020-01-15       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.